Skip to main content

Somatuline Depot Side Effects

Generic name: lanreotide

Medically reviewed by Drugs.com. Last updated on Jul 25, 2022.

Note: This document contains side effect information about lanreotide. Some dosage forms listed on this page may not apply to the brand name Somatuline Depot.

Applies to lanreotide: subcutaneous solution.

Serious side effects of Somatuline Depot

Along with its needed effects, lanreotide (the active ingredient contained in Somatuline Depot) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lanreotide:

More common

Incidence not known

Other side effects of Somatuline Depot

Some side effects of lanreotide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lanreotide: subcutaneous solution.

General

The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools

Common (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia

Uncommon (0.1% to 1%): Pancreatitis, feces discolored

Frequency not reported: Steatorrhea[Ref]

In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.[Ref]

Hepatic

Very common (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis

Common (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation

Uncommon (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal

Frequency not reported: Cholecystitis

Postmarketing reports: Steatorrhea, pancreatitis[Ref]

Cardiovascular

Very common (10% or more): Bradycardia (18%), hypertension (14%)

Common (1% to 10%): Sinus bradycardia

Uncommon (0.1% to 1%): Other cardiac adverse drug reactions[Ref]

Local

Very common (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)

Postmarketing reports: Persisting induration, injection site abscess[Ref]

Metabolic

Very common (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)

Common (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased

Uncommon (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated[Ref]

Hematologic

Very common (10% or more): Anemia (14%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (19%), arthralgia (11%)[Ref]

Nervous system

Very common (10% or more): Headache (16%)

Common (1% to 10%): Dizziness

Postmarketing reports: Dysautonomia[Ref]

Respiratory

Common (1% to 10%): Dyspnea[Ref]

Psychiatric

Common (1% to 10%): Depression

Uncommon (0.1% to 1%): Insomnia[Ref]

Other

Common (1% to 10%): Fatigue

Uncommon (0.1% to 1%): Hot flush, asthenia

Postmarketing reports: Malaise[Ref]

Immunologic

Common (1% to 10%): Anti-lanreotide (the active ingredient contained in Somatuline Depot) antibodies[Ref]

Hypersensitivity

Frequency not reported: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)[Ref]

Dermatologic

Common (1% to 10%): Alopecia, hypotrichosis[Ref]

Endocrine

Rare (less than 0.1%): Clinical hypothyroidism

Frequency not reported: Slight decreases in thyroid function[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Somatuline Depot (lanreotide). Ipsen Inc. 2007.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.